Dexmedetomidine alleviates lipopolysaccharide-induced lung injury in Wistar rats

Xuetao Yan; Xiaoli Cheng; Liwen Zhou; Xianghu He; Wenzhong Zheng; Hu Chen

doi:10.18632/oncotarget.17899

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Dexmedetomidine alleviates lipopolysaccharide-induced lung injury in Wistar rats

Xuetao Yan _, Xiaoli Cheng, Liwen Zhou, Xianghu He, Wenzhong Zheng and Hu Chen

PDF | HTML | How to cite

Oncotarget. 2017; 8:44410-44417. https://doi.org/10.18632/oncotarget.17899

Metrics: PDF 1589 views | HTML 2698 views | ?

Abstract

Xuetao Yan1, Xiaoli Cheng2, Liwen Zhou3, Xianghu He4, Wenzhong Zheng1 and Hu Chen1

1Department of Anesthesiology, Shenzhen Bao’an Maternity and Child Health Hospital, Shenzhen, 518100, China

2Department of Pharmacy, Shenzhen Bao’an Maternity and Child Health Hospital, Shenzhen, 518100, China

3Department of Anesthesiology, Xiangyang Central Hospital, Xiangyang, 441021, China

4Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China

Correspondence to:

Xuetao Yan, email: [email protected]

Keywords: dexmedetomidine, lung injury, inflammation, oxidative stress, Nrf2

Received: April 07, 2017 Accepted: April 27, 2017 Published: May 16, 2017

ABSTRACT

This study aimed to investigate the protective effects of dexmedetomidine on lipopolysaccharide (LPS)-induced lung injury in Wistar rats. 24 female Wistar rats were randomly assigned into 3 groups (n = 8): a control group, a LPS-challenged group, and a LPS plus dexmedetomidine group. Inflammation, oxidative stress, Nrf2/Keap1, and Akt signal were determined. The results showed that LPS caused inflammation and oxidative stress via increasing pro-inflammatory cytokines and oxidative products. Dexmedetomidine treatment alleviated inflammation and oxidative stress in LPS-challenged rats. Nrf2/Keap1 was inhibited and Akt signal was activated in the lung after exposure to LPS, while dexmedetomidine activated Nrf2/Keap1, which further mediated expressions of antioxidant genes. In conclusion, dexmedetomidine alleviated inflammatory response and oxidative stress in LPS-induced lung injury in rats via influencing Nrf2/Keap1 signal.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17899

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Dexmedetomidine alleviates lipopolysaccharide-induced lung injury in Wistar rats

Abstract